logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report
      • Health Canada Priority Review & Project Orbis Sub-Report
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r.png
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report
      • Health Canada Priority Review & Project Orbis Sub-Report
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

Files Under pCPA Consideration for Greater Than 6 Months Drops Significantly

May 12, 2021
-
Market Access News
-
Posted by MORSE - 4 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): April 2021 Trends and Insights

 

April 2021 Highlights:

  • 5 products completed CADTH review
  • 6 products initiated pCPA negotiations
  • 4 negotiations were completed with an LOI
  • 1 negotiation was closed without an LOI
  • 0 file was closed without negotiation

 

Key Take-Aways:

  • The volume of files under consideration has remained relatively high and stable for the last 5 months (27-30), although the ratio of oncology to non-oncology files shifted slightly. The average time under consideration dropped slightly in April but remains high compared to the same time last year.
  • The pCPA initiated negotiations for 6 files, more than we have seen in the last few months. Of those files, 3 had been under consideration for more than 6 months (Beovu, Stelara and Mayzent), perhaps signalling uptake through the Targeted Negotiation Process (TNP) (although that is speculative). Two of the files picked up in less than 6 months, Soliris and Stelara, are already under negotiation for other indications. The workload of the pCPA remains high with 62 files under their purview.
  • The 4 successfully completed files in April were all negotiated quite quickly. Adcetris, with previous LOIs, had 2 indications negotiated in 82 days. Two biosimilars, the second enoxaparin and the 4th pegfilgrastim, negotiated in 77 and 82 days, respectively. April also saw the close of Xultophy, which had been under negotiation for well over a year.
  • April saw the highest number of non-oncology files under negotiation this past year. This finding, coupled with the significant drop in files under consideration over the last few months, may signal utilization of the TNP.

 

Files Under pCPA Consideration*:

CADTH issued 5 new recommendations in April (29 files under pCPA consideration as of April 30th) – same as 29 in March.

Note: In our previous issue of the pCPA update, one of the 5 recommendations issued in March was for Vonvendi (von Willebrand Factor), which went through the Interim Plasma-Protein Products Review Process and will go to Canadian Blood Services (CBS) and not pCPA for next steps (see CADTH CBS PPP Process)

PRODUCT INDICATION SPONSOR Type REC’N* DATE
Enspryng (satralizumab) Neuromyelitis optica spectrum disorder Hoffmann-La Roche Non-oncology 2021-04-21
Ruzurgi (amifampridine) Lambert-Eaton myasthenic syndrome Médunik Canada Inc. Non-oncology 2021-04-20
Sarclisa (isatuximab) Multiple Myeloma Sanofi Genzyme Oncology 2021-04-19
Bavencio (Avelumab) Urothelial Carcinoma (UC) EMD Serono a Division of EMD Inc. Canada Oncology 2021-04-08
Remsima SC (Infliximab SC) Rheumatoid arthritis Celltrion Healthcare Co., Ltd Biosimilar** 2021-04-22

*Note: Since MORSE began issuing pCPA updates, we have defined “under pCPA consideration” as the time between receipt of a final recommendation or notification to implement from CADTH. This does not match the date that the pCPA website has recently started to publish (which starts after issuance of the acknowledgement letter which is not publicly available). This is to ensure consistency of data analysis historically.
**CADTH stopped reviewing biosimilars since June 1st, 2019. Remsima SC represents a new route of administration for infliximab (subcutaneous) for which there is no reference product authorized in Canada. As such Remsima SC was reviewed by CADTH through the tailored review process.

Signals Decoded:

 

The volume of files under consideration has remained relatively high and stable for the last 5 months (27-30), although the ratio of oncology to non-oncology files shifted slightly. The average time under consideration dropped slightly in April but remains high compared to the same time last year.

Negotiation Initiation:

The pCPA initiated 6 new negotiations in April (33 active negotiations as of April 30th) – up from 32 in March.

PRODUCT INDICATION SPONSOR CATEGORY INITIATE DATE TTI*
Trurapi (insulin aspart) Diabetes Mellitus, Type 1 & 2  Sanofi-Aventis Biosimilar 2021-04-27 N/A
Entyvio SC (Vedolizumab) Crohn’s Disease Takeda Canada Inc. Non-oncology 2021-04-15 84
Soliris (Eculizumab) Generalized Myasthenia Gravis (gMG) Alexion Pharma GMBH Non-oncology 2021-04-01 164
Mayzent (siponimod) Secondary progressive Multiple sclerosis (SPMS) Novartis Pharma Canada Inc. Non-oncology 2021-04-27 280
Stelara (Ustekinumab) Ulcerative colitis Janssen Inc. Non-oncology 2021-04-27 285
Beovu (brolucizumab) Macular degeneration, age-related Novartis Pharma Canada Inc. Non-oncology 2021-04-27 341
Venclexta (venetoclax)** In combination with obinutuzumab for the treatment of Chronic Lymphocytic Leukemia AbbVie Corporation Oncology 2021-02-23 83

*Time to Initiation (TTI) – Time from final recommendation or notification to implement to pCPA initiation in calendar days
**Correction from February

Signals Decoded:

The pCPA initiated negotiations for 6 files, more than we have seen in the last few months. Of those files, 3 had been under consideration for more than 6 months (Beovu, Stelara and Mayzent), perhaps signalling uptake through the Targeted Negotiation Process (TNP) (although that is speculative). Two of the files picked up in less than 6 months, Soliris and Stelara, are already under negotiation for other indications. The workload of the pCPA remains high with 62 files under their purview.

 

Completed/Closed Negotiations:

The pCPA completed 4 negotiations with a Letter of Intent (LOI) and closed 1 negotiation without an LOI in April 2021.

 

Completed Negotiations

PRODUCT INDICATION Sponsor Type Status LOI DATE TTN*
Adcetris (Brentuximab Vedotin) Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) Seattle Genetics Inc. Oncology Completed 2021-04-28 82
Adcetris (Brentuximab Vedotin) Primary Cutaneous Anaplastic Large Cell Lymphoma (or CD30- Expressing Mycosis Fungoides) Seattle Genetics Inc. Oncology Completed 2021-04-28 82
Inclunox (enoxaparin) Deep Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism Sandoz Canada Inc. Biosimilar Completed 2021-04-15 77
Nyvepria (pegfilgrastim) febrile neutropenia in non-myeloid malignancies Pfizer Canada Inc. Biosimilar Completed 2021-04-05 82

* TTN = Time to Negotiate in calendar days

 

Closed Negotiations

PRODUCT INDICATION Sponsor Type Status LOI DATE TTN*
Xultophy (insulin degludec + liraglutide) Diabetes mellitus, Type 2 Novo Nordisk Non-oncology Closed 2021-04-26 451

* TTN = Time to Negotiate in calendar days

Signals Decoded:

 

The 4 successfully completed files in April were all negotiated quite quickly. Adcetris, with previous LOIs, had 2 indications negotiated in 82 days. Two biosimilars, the second enoxaparin and the 4th pegfilgrastim, negotiated in 77 and 82 days, respectively.  April also saw the close of Xultophy, which had been under negotiation for well over a year.

 

 

Signals Decoded:

 

April saw the highest number of non-oncology files under negotiation this past year. This finding, coupled with the significant drop in files under consideration over the last few months, may signal utilization of the TNP.

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share
Tags
Biosimilars
CADTH
CDEC
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
pERC
← PREVIOUS POST
New INESSS Evaluation Fee Schedule
NEXT POST →
MORSE Consulting Releases 2021 Edition of the Canadian Reimbursement and Forecasting Timelines Report

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
Files Under pCPA Consideration for Greater Than 6 Months Drops Significantly